4LN2.F CAPRICOR THERAP. DL-001

Healthcare Biotechnology Frankfurt Exchange
8.23 EUR
Close of Nov 11, 2026
2.58 30.10
Market cap
EUR 479M
P/E
-
P/B
2.26x
ROE
-74.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 4LN2.F undervalued?

Graham number

The Graham number of CAPRICOR THERAP. DL-001 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CAPRICOR THERAP. DL-001 fundamental analysis

No fundamental analysis for CAPRICOR THERAP. DL-001 yet.

CAPRICOR THERAP. DL-001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CAPRICOR THERAP. DL-001

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is i…

Full company profile